RFPの耐性 (前編)
スポンサーリンク
概要
- 論文の詳細を見る
1. The MIC of Rifampicin to tubercle bacilli isolated from 1, 779 Rifampicin untreated patients who were admitted to our hospital from June 1970 to June 1975 was studied by using 1% Ogawa medium.<BR>2. There were 4 cases resistant to 50mcg of Rifampicin, but 3 of them had enough reason to be considered as they had been treated already by the drug, and the technical failure was suspected in the remaining one case.<BR>3. By indirect method, there were 7 patients (0.7%), whose bacilli grew 1% to 10% on 10 mcg of Rifampicin medium among 1, 065 patients and no bacilli grew over 11% on that medium. However, by direct method, there were 115 cases (16.1%) whose bacilli grew 1% to 10% on 10 mcg medium among 714 cases and 6 cases (0.8%) over 11%.<BR>By the direct method, bacilli grew more easily than by the indirect method on the medium containing the critical drug concentration; in other words, the drug resistance was expressed higher by the direct method (Table 2). The growth of bacilli seems to be more active on the direct method.<BR>4. The bacilli from the patients admitted after July 1974, showed apparently higher rate of resistance than those admitted before (Table 3-4). This can be explained by the change in the stopper from cork type to M type. The latter stopper was invented by Futamura of our laboratory, which is usually air tight but allows the air leak into a tube any time when neccessary. Moreover it prevents the drying up of the medium often seen when the air enters too much. Thus, the improvement of the growing condition of bacilli was achieved.<BR>5. MIC of Rifampicin was 10% for the indirect method and 50% for the direct method with a few exception both on the 10mcg Rifampicin medium. However, for the clinical significance of Rifampicin resistance, the criteria seem to be more reasonable if we take 50% growth or more on the 10 mcg Rifampicin medium, and we may add 1% growth or more on the 50mcg Rifampicin medium which will be discussed in the 2nd report.
- 日本結核病学会の論文
著者
関連論文
- 外来性再感染によると思われる4症例について-4-総括,討論,結論
- 外来性再感染によると思われる4症例について-3-症例4および症例2,3,4の相互関連その他の検討
- 外来性再感染によると思われる4症例について-2-症例3について
- 外来性再感染によると思われる4症例について-1-症例1および症例2について
- 結核性膿胸患者の治療に関する研究
- 燒灼336名について
- ^Hg : グルタチオンによる肺癌シンチグラフィーの臨床的価値
- 肺癌の放射性第2塩化水銀のマクロオートラジオグラムと組織変化の検討 : 関東支部 : 第39回支部活動
- 11.肺癌における放射性水銀の診断的価値 : 第37回支部会 : 関東支部
- RFPを含む3方式による肺結核6ヵ月化療の対照試験 (第2報) : 治療終了後1年目の成績
- RFPを含む3方式による肺結核6ヵ月化療の対照試験 (第1報)
- 外来性再感染によると思われる4症例について : 第4部総括, 討論, 結論
- 外来性再感染によると思われる4症例について : 第3部 症例4および症例2, 3, 4の相互関連その他の検討
- 外来性再感染によると思われる4症例について : 第2部症例3について
- 外来性再感染によると思われる4症例について : 第1部症例1および症例2について
- 一次薬3者併用におけるSM毎日と週2回の比較 : 特に耐性限界を考慮して (第2報)
- RFPの耐性 (後編)
- RFPの耐性 (前編)
- 次薬3者併用におけるSM毎日と週2回の比較 : ―特に耐性限界を考慮しで(第1報)―
- SM, INH, PASの臨床耐性限界
- 抗結核剤の1回および分服法の比較
- Rifampicinによる肺結核の再治療
- Rifampicinによる肺結核の再治療
- Ethambutolによる視力障害
- D-2,2-(Ethylenediimino)di-1-butanol[Ethambutol, Ebutol]の臨床成績
- D-2, 2-(Ethylenediimino)di-1-butanol[Ethambutol,Ebuto1]の臨床成績
- エタンブトールの体内分布とその代謝